// App-Quantinova.ai

230 : LEAP-005: A phase II multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors: Results from the gastric cancer cohort.

Researchers

Presenter

  • Hyun Cheol Chung

Principal Investigators

  • Carlos Gomez-Roca

  • Federico Longo

  • Eduardo Yanez

  • Eduardo Castanon Alvarez

  • Donna Graham

  • Mark Doherty

  • Philippe Cassier

  • Juanita Suzanne Lopez

  • Bristi Basu

  • Andrew Eugene Hendifar

  • Corinne Maurice-Dror

  • Sanjeev Singh Gill

  • Razi Ghori

  • Peter Kubiak

  • Fan Jin

  • Kevin Glen Norwood

  • Esma Saada-Bouzid

Medical Centers

  • Yonsei Cancer Center, Yonsei University College of Medicine, Seoul,...

  • Royal Brisbane & Women's Hospital and University of Queensland, Brisbane, Australia

  • Institut Claudius Regaud, IUCT-Oncopole, CRCT, Inserm, Toulouse, France

  • Hospital Universitario Ramón y Cajal, IRYCIS, CIBERONC, Madrid, Spain

  • Hematology-Oncology Unit, Department of Internal Medicine, School of Medicine,Universidad de la Frontera,Temuco,Chili

  • Clinica Universidad de Navarra, Pamplona, Spain

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Sunnybrook Health Sciences Center and University of Toronto, Toronto, Canada

  • Centre Leon Berard, Lyon, France

  • Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, London, United Kingdom

  • Department of Oncology, University of Cambridge, Cambridge, United Kingdom

  • Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA

  • The Rappaport Faculty of Medicine, Technion, Haifa, Israel

  • The Alfred Hospital, Melbourne, Australia

  • Merck & Co., Inc., Kenilworth, NJ

  • Eisai Inc, Woodcliff Lake, NJ

  • Centre de Lutte Contre le Cancer, Antoine Lacassagne, Nice, France

Locations

  • Republic of South Korea

  • Australia

  • France

  • Spain

  • Chile

  • United Kingdom

  • Canada

  • United States

  • Israel

Companies

  • Merck & Co., Inc.

  • Eisai Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Gastric Cancer

  • Solid malignancies

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Pembrolizumab

  • Lenvatinib

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

  • Cohort

Phase

  • II

Study Id's

  • NCT03797326

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved